TCR-like Platform
Precision Gene Therapy for Cancer Immunotherapy
TCR-LIKE PLATFORM
TCR-like is the first platform that allows the physiological expression of the CAR receptor using viral vectors.
TCR-like platform represents a creative platform to the expression of any gene with activity in immunotherapy, including CAR, mimicking the natural expression of the T-cell receptor interaction.
Unlike the current CAR-T cell therapy, which increase the expression of the CAR receptor in the membrane (overexpression), producing an overstimulation and tonic signaling (activity in the absence of tumors cells) that triggers premature exhaustion and failure of CAR-T cell's fitness, our TCR-like platform:
- 1. Provides a self-control of the CAR expression after tumor encounter.
- 2. Prevent overstimulation.
- 3. Improve the fitness of the CAR-T cell therapy.
This platform can generate TCR-like-CAR-T cells with moderate and high CAR-density with improved properties.
Our proof-of-concept has reported significant differences in:
Lack of Efficacy
TCR-like provide lower levels of exhaustion, tonic signalling and activation markers in the absence tumor cells.
Severe Toxicities
TCR-like provide lower secretion of pro-inflamatory cytokines that mediate Cytokine Release Syndrome (CRS).
Manufacturing
TCR-like provide higher specific lysis and more stem and fit phenotype. Reducing the manufacturing process.
Current CAR-T cells
TCR-like® CAR-T cells
Resting
- High Tonic Signaling
- Chronic Activation
Stimulation
Exhaustion & Toxicity
Resting
- No Tonic Signaling
- Clean Surface
Stimulation
Regulated Expression